ADC Therapeutics SA (ADCT) stock
ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.34−0.07 (-4.96%)
Close on Nov 13, 2026Market cap $171.08MP/E –Yield –
ADC Therapeutics total assets
Total assets on the balance sheet at the end of each period.
ADC Therapeutics's total assets was $255.86M at Sep 30, 2026. For fiscal 2025 it was $323.15M, up 0.4% from the year before. The highest annual figure on record is $617.97M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $323.15M | +0.4% |
| FY2024 | Dec 31, 2024 | $321.98M | -9.2% |
| FY2023 | Dec 31, 2023 | $354.78M | -27.7% |
| FY2022 | Dec 31, 2022 | $490.86M | -20.6% |
| FY2021 | Dec 31, 2021 | $617.97M | +20.3% |
| FY2020 | Dec 31, 2020 | $513.69M | +273.1% |
| FY2019 | Dec 31, 2019 | $137.68M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $255.86M | -11.7% |
| Q2 FY2026 | Jun 30, 2026 | $279.38M | -13.1% |
| Q1 FY2026 | Mar 31, 2026 | $291.50M | +7.0% |
| Q4 FY2025 | Dec 31, 2025 | $323.15M | +0.4% |
| Q3 FY2025 | Sep 30, 2025 | $289.76M | -17.0% |
| Q2 FY2025 | Jun 30, 2025 | $321.56M | -13.5% |
| Q1 FY2025 | Mar 31, 2025 | $272.54M | -11.5% |
| Q4 FY2024 | Dec 31, 2024 | $321.98M | -9.2% |
| Q3 FY2024 | Sep 30, 2024 | $349.08M | -25.2% |
| Q2 FY2024 | Jun 30, 2024 | $371.78M | -26.7% |
| Q1 FY2024 | Mar 31, 2024 | $307.97M | -34.1% |
| Q4 FY2023 | Dec 31, 2023 | $354.78M | -27.7% |
| Q3 FY2023 | Sep 30, 2023 | $466.90M | -12.2% |
| Q2 FY2023 | Jun 30, 2023 | $507.30M | -2.5% |
| Q1 FY2023 | Mar 31, 2023 | $467.67M | -19.6% |
| Q4 FY2022 | Dec 31, 2022 | $490.86M | -20.6% |
| Q3 FY2022 | Sep 30, 2022 | $531.76M | -16.6% |
| Q2 FY2022 | Jun 30, 2022 | $520.46M | +12.1% |
| Q1 FY2022 | Mar 31, 2022 | $581.89M | +26.0% |
| Q4 FY2021 | Dec 31, 2021 | $617.97M | +20.3% |
| Q3 FY2021 | Sep 30, 2021 | $637.98M | +363.4% |
| Q2 FY2021 | Jun 30, 2021 | $464.39M | – |
| Q1 FY2021 | Mar 31, 2021 | $461.71M | – |
| Q4 FY2020 | Dec 31, 2020 | $513.69M | – |
| Q4 FY2019 | Dec 31, 2019 | $137.68M | – |
See a number that looks wrong?